Aktis Oncology (NASDAQ:AKTS) Trading 7.4% Higher – Should You Buy?

Aktis Oncology (NASDAQ:AKTS) shares traded up 7.4% during trading on Tuesday . The stock traded as high as $19.49 and last traded at $19.6150. 14,076 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 326,991 shares. The stock had previously closed at $18.27.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings began coverage on Aktis Oncology in a research report on Tuesday. They issued a “sell (d)” rating for the company. HC Wainwright upped their target price on Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Leerink Partners began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Aktis Oncology Price Performance

The business’s 50-day moving average price is $18.72.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share (EPS) for the quarter. The company had revenue of $1.87 million during the quarter. On average, research analysts predict that Aktis Oncology will post -1.56 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.